216 related articles for article (PubMed ID: 12604683)
1. Modification of noradrenaline release in pithed spontaneously hypertensive rats by I1-binding sites in addition to alpha2-adrenoceptors.
Raasch W; Jungbluth B; Schäfer U; Häuser W; Dominiak P
J Pharmacol Exp Ther; 2003 Mar; 304(3):1063-71. PubMed ID: 12604683
[TBL] [Abstract][Full Text] [Related]
2. Norepinephrine release is reduced by I(1)-receptors in addition to alpha(2)-adrenoceptors.
Raasch W; Jungbluth B; Schäfer U; Häuser W; Dominiak P
Ann N Y Acad Sci; 2003 Dec; 1009():270-3. PubMed ID: 15028598
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine.
Bock C; Niederhoffer N; Szabo B
Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):262-71. PubMed ID: 10344524
[TBL] [Abstract][Full Text] [Related]
4. Evidence that some imidazoline derivatives inhibit peripherally the vasopressor sympathetic outflow in pithed rats.
Monroy-Ordoñez EB; Villalón CM; Cobos-Puc LE; Márquez-Conde JA; Sánchez-López A; Centurión D
Auton Neurosci; 2008 Dec; 143(1-2):40-5. PubMed ID: 18774761
[TBL] [Abstract][Full Text] [Related]
5. Presynaptic effects of moxonidine in isolated buffer perfused rat hearts: role of imidazoline-1 receptors and alpha2-adrenoceptors.
Schäfer U; Burgdorf C; Engelhardt A; Kurz T; Richardt G
J Pharmacol Exp Ther; 2002 Dec; 303(3):1163-70. PubMed ID: 12438540
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of the inhibition by moxonidine and agmatine on the cardioaccelerator sympathetic outflow in pithed rats.
Cobos-Puc LE; Villalón CM; Ramírez-Rosas MB; Sánchez-López A; Lozano-Cuenca J; Gómez-Díaz B; MaassenVanDenBrink A; Centurión D
Eur J Pharmacol; 2009 Aug; 616(1-3):175-82. PubMed ID: 19527708
[TBL] [Abstract][Full Text] [Related]
7. Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction.
Raasch W; Schäfer U; Qadri F; Dominiak P
Br J Pharmacol; 2002 Feb; 135(3):663-72. PubMed ID: 11834614
[TBL] [Abstract][Full Text] [Related]
8. Interruption of central neuronal pathway of imidazoline I1 receptor mediates the hypertensive effect of cyclosporine in rats.
El-Mas MM; Omar AG; Helmy MM; Mohy El-Din MM
Brain Res; 2009 Jan; 1248():96-106. PubMed ID: 19028461
[TBL] [Abstract][Full Text] [Related]
9. Involvement of central alpha1- and alpha2-adrenoceptors on cardiovascular responses to moxonidine.
Moreira TS; Takakura AC; Menani JV; Colombari E
Eur J Pharmacol; 2007 Jun; 563(1-3):164-71. PubMed ID: 17382316
[TBL] [Abstract][Full Text] [Related]
10. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Ernsberger P
J Pharmacol Exp Ther; 2003 Aug; 306(2):646-57. PubMed ID: 12756274
[TBL] [Abstract][Full Text] [Related]
11. Involvement of presynaptic imidazoline receptors in the alpha 2-adrenoceptor-independent inhibition of noradrenaline release by imidazoline derivatives.
Göthert M; Molderings GJ
Naunyn Schmiedebergs Arch Pharmacol; 1991 Mar; 343(3):271-82. PubMed ID: 1678140
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological analysis of the cardiac sympatho-inhibitory actions of moxonidine and agmatine in pithed spontaneously hypertensive rats.
Cobos-Puc LE; Sánchez-López A; Centurión D
Eur J Pharmacol; 2016 Nov; 791():25-36. PubMed ID: 27565220
[TBL] [Abstract][Full Text] [Related]
13. Moxonidine: a new antiadrenergic antihypertensive agent.
Prichard BN; Graham BR; Owens CW
J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of locus coeruleus neurons by non-I1/I2-type imidazoline receptors: an in vivo and in vitro electrophysiological study.
Ugedo L; Pineda J; Ruiz-Ortega JA; Martín-Ruiz R
Br J Pharmacol; 1998 Dec; 125(8):1685-94. PubMed ID: 9886760
[TBL] [Abstract][Full Text] [Related]
15. Commissural nucleus of the solitary tract regulates the antihypertensive effects elicited by moxonidine.
Totola LT; Alves TB; Takakura AC; Ferreira-Neto HC; Antunes VR; Menani JV; Colombari E; Moreira TS
Neuroscience; 2013 Oct; 250():80-91. PubMed ID: 23850502
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
17. Receptors involved in moxonidine-stimulated atrial natriuretic peptide release from isolated normotensive rat hearts.
Mukaddam-Daher S; Menaouar A; Gutkowska J
Eur J Pharmacol; 2006 Jul; 541(1-2):73-9. PubMed ID: 16774751
[TBL] [Abstract][Full Text] [Related]
18. Involvement of pertussis toxin-sensitive and -insensitive mechanisms in alpha-adrenoceptor modulation of noradrenaline release from rat sympathetic neurones in tissue culture.
Hill CE; Powis DA; Hendry IA
Br J Pharmacol; 1993 Sep; 110(1):281-8. PubMed ID: 8106104
[TBL] [Abstract][Full Text] [Related]
19. Involvement of alpha-2 adrenoceptors in the effects of moxonidine on intestinal motility and fluid transport.
Liu L; Coupar IM
J Pharmacol Exp Ther; 1997 Dec; 283(3):1367-74. PubMed ID: 9400012
[TBL] [Abstract][Full Text] [Related]
20. Dual effect of agmatine in the bisected rat vas deferens.
Santos WC; Smaili SS; Jurkiewicz A; Piçarro I; Garcez-do-Carmo L
J Pharm Pharmacol; 2003 Mar; 55(3):373-80. PubMed ID: 12724044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
